The total return over the past 12 months is +24.99% vs. +16.94% for the S&P 500. So far it's up -13.53% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +24.99% | +38.95% | +7.38% | N/A | N/A | N/A |
| Total Return CAGR | +24.99% | +38.95% | +7.38% | N/A | N/A | N/A |
| Revenue CAGR | +202.39% | +400.68% | +62.61% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
BridgeBio Pharma, Inc. (BBIO)
| Year | Start price | End price | BBIO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $76.49 | $66.14 | (13.53%) | +14.51% | (28.04%) |
| 2025 | $27.44 | $76.49 | +178.75% | +17.72% | +161.03% |
| 2024 | $40.37 | $27.44 | (32.03%) | +24.89% | (56.92%) |
| 2023 | $7.62 | $40.37 | +429.79% | +26.19% | +403.60% |
| 2022 | $16.68 | $7.62 | (54.32%) | (18.17%) | (36.15%) |
| 2021 | $71.11 | $16.68 | (76.54%) | +28.74% | (105.28%) |
| 2020 | $35.05 | $71.11 | +102.88% | +18.37% | +84.51% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
